| Title |
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
|
|---|---|
| Published in |
OncoTargets and therapy, April 2017
|
| DOI | 10.2147/ott.s124008 |
| Pubmed ID | |
| Authors |
Lars M Wagner, Val R Adams |
| Abstract |
While remarkable advances have been made in the treatment of pediatric leukemia over the past decades, new therapies are needed for children with advanced solid tumors and high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| Unknown | 96 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 14 | 14% |
| Researcher | 11 | 11% |
| Student > Ph. D. Student | 10 | 10% |
| Student > Postgraduate | 9 | 9% |
| Student > Master | 9 | 9% |
| Other | 18 | 19% |
| Unknown | 26 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 36% |
| Biochemistry, Genetics and Molecular Biology | 12 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Agricultural and Biological Sciences | 5 | 5% |
| Immunology and Microbiology | 3 | 3% |
| Other | 8 | 8% |
| Unknown | 29 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 September 2021.
All research outputs
#8,091,498
of 25,707,225 outputs
Outputs from OncoTargets and therapy
#439
of 3,013 outputs
Outputs of similar age
#118,968
of 324,863 outputs
Outputs of similar age from OncoTargets and therapy
#15
of 92 outputs
Altmetric has tracked 25,707,225 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,013 research outputs from this source. They receive a mean Attention Score of 2.9. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,863 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.